Union Bancaire Privee UBP SA Boosts Stake in AbbVie Inc. $ABBV

Union Bancaire Privee UBP SA lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 11.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 443,006 shares of the company’s stock after acquiring an additional 46,028 shares during the period. AbbVie makes up 1.4% of Union Bancaire Privee UBP SA’s investment portfolio, making the stock its 12th biggest position. Union Bancaire Privee UBP SA’s holdings in AbbVie were worth $95,348,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in ABBV. Ellenbecker Investment Group boosted its holdings in shares of AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after purchasing an additional 44 shares in the last quarter. Security National Bank of Sioux City Iowa IA raised its holdings in shares of AbbVie by 0.3% during the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after buying an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC lifted its position in AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after buying an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC boosted its stake in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after buying an additional 45 shares in the last quarter. Finally, Willner & Heller LLC grew its position in AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after acquiring an additional 46 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $206.32 on Friday. The stock has a market capitalization of $364.80 billion, a P/E ratio of 87.42, a PEG ratio of 0.72 and a beta of 0.34. The business has a 50 day simple moving average of $223.41 and a two-hundred day simple moving average of $224.71. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.25% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie signed a multi‑year collaboration with Alloy Therapeutics to develop a next‑generation antibody discovery platform, which could expand AbbVie’s ability to find antibodies for targets current tech struggles with — a pipeline and long‑term revenue positive. AbbVie, Alloy Therapeutics Ink Deal to Develop Next‑Gen Antibody Platform
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) published global consumer research and new educational initiatives supporting evolving, multimodal aesthetic demand — a steadying, growth‑oriented business line that diversifies AbbVie beyond immunology. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: Several market writeups note a recent share‑price pullback and discuss valuation after the selloff — useful for investors weighing whether the drop is a buying opportunity or a sign of longer‑term competitive risk. Assessing AbbVie (ABBV) Valuation After The Recent Share Price Pullback
• Negative Sentiment: Major negative catalyst — Johnson & Johnson’s Icotyde (first oral IL‑23 inhibitor) won FDA approval. An oral, once‑daily option raises convenience and pricing/market‑share questions for injectable Skyrizi, which has been AbbVie’s key growth driver. That approval is the main reason for the near‑term stock weakness. J&J wins FDA nod for psoriasis pill that aims to compete with top‑selling injections
• Negative Sentiment: Generic competition: Breckenridge launched a generic Milnacipran (Savella® equivalent), which can pressure revenue in the pain management segment where AbbVie previously sold Savella. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ABBV shares. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Royal Bank Of Canada started coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.